Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Musculoskeletal | Immunology | Family Medicine
Disease Category: Rheumatoid Arthritis
Location: United States, MD

Clinical Trial Details

Overview

Research Study Summary

Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of JAK-3, Compared to Methotrexate Naive patients with Rheumatoid Arthritis

Purpose

Do you have Rheumatoid arthritis? You may qualify to participate in a clinical research study.

JAK-3 inhibitors represent the first oral class of medication to have a demonstrable effect on a targeted component of the immune system. Seropositive rheumatoid arthritis patients are needed for this study. This double-blinded placebo controlled phase III trial is for a 2 year period, but does not limit patients to prior drug failures.

To Learn more
Phase

3

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Duration

2 Years

Facility Type

N/A

Contact

The Center for Rheumatology and Bone Research
2730 University Blvd West, Suite 306
Wheaton, MD 20902
Phone: 301 942-6610
Fax: 301 942-7833

View Map

Research Center Information: The Center for Rheumatology and Bone Research

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 169936

Date Last Changed: July 23, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.